Core Viewpoint - Federal Pharmaceutical's wholly-owned subsidiary, Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., has received clinical trial approval for its innovative drug UBT251 injection for the treatment of moderate to severe obstructive sleep apnea (OSA) in China [1] Group 1: Drug Development - UBT251 injection is a multi-target peptide receptor agonist developed independently by Federal Biotechnology, which acts on GLP-1, GIP, and GCG receptors to lower blood sugar and inhibit weight gain [1] - The drug is expected to address significant unmet clinical needs in the OSA treatment field, similar to GLP-1 class weight loss medications [1] Group 2: Clinical Trials and Research - UBT251 injection is currently undergoing Phase II clinical trials in China for indications including overweight or obesity, type 2 diabetes, metabolic-associated fatty liver disease, and chronic kidney disease [1] - As the first chemically synthesized GLP-1/GIP/GCG tri-target receptor agonist new drug in China, UBT251 positions the company prominently in this research area [1] Group 3: Future Outlook - The company aims to continue its commitment to new product development, enhancing its competitiveness and creativity in the biopharmaceutical industry, which is expected to generate greater returns for the company and its shareholders [1]
联邦制药(03933)：UBT251 注射液OSA适应症获临床试验默示许可